Why the study?
Does oral cyclophosphamide cause bladder complications in patients with systemic lupus erythematosus or rheumatoid arthritis?
Does oral cyclophosphamide cause bladder complications in patients with systemic lupus erythematosus or rheumatoid arthritis?
Oral cyclophosphamide is associated with late-occurring serious bladder toxicities, including hemorrhagic cystitis and carcinoma, in patients with nonmalignant inflammatory rheumatic conditions.
Answers are grounded in this paper and cite their sources.
Associated with late bladder toxicity in rheumatic disease; extends signals but should not yet change practice.
The bladder complications of 54 patients treated with oral cyclophosphamide for systemic lupus erythematosus (43) or rheumatoid arthritis (11) were reviewed. During an observation period of 241 patient years, we saw seven cases of acute hemorrhagic cystitis and two cases of transitional cell carcinoma of the bladder. Bladder carcinoma was identified 28 and 60 months after withdrawal of the drug and resulted in the death of one patient. The late-occurring serious toxicities of cyclophosphamide should limit the use of the drug in the treatment of nonmalignant inflammatory rheumatic conditions.
No takes yet. Share an insight, caveat, or question.
Paul H. Plötz (1979) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: